Upcoming PDUFA Dates Could Be Major Catalysts For These 3 Biotech Stocks

In the biotech realm, the author of today’s article notes that “PDUFA (Prescription Drug User Fee Act) dates – the deadline of the FDA’s review of new drugs – determine whether a treatment is fit for purpose or not and a yay or nay can act as a major catalyst to send shares either soaring or crashing.” As such, he highlights three biotech stocks with approaching PDUFA dates that are Buy-rated and where analysts are predicting strong gains. For these three stocks, CLICK HERE.